X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Tom Wilbur

Tom Wilbur Tom Wilbur is a director of public affairs at PhRMA focusing on the organization’s federal advocacy priorities including intellectual property and Medicare Part D. Prior to joining PhRMA, Tom worked in national and state politics for nearly a decade, most recently on Capitol Hill as a strategic communicator and campaign manager. Tom is a proud Michigander and in his spare time enjoys reading, live music, and spending time with friends and family cheering on Detroit sports teams.

Recent Posts

Pelosi’s radical plan would leave patients with sickle cell disease behind

By Tom Wilbur  |    November 14, 2019
Sickle cell disease (SCD) is the most commonly inherited genetic blood disorder, affecting nearly 100,000 children and adults in the United States. Three million Americans carry the sickle cell...   Read More

Pelosi’s radical plan would leave patients with rare pediatric diseases behind

By Tom Wilbur  |    November 7, 2019
There are about 7,000 rare diseases and half of these affect children. According to the National Institutes of Health (NIH), 30 million Americans, or 10 percent of the population, have one of the...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation

By Tom Wilbur  |    October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.   Read More

Pelosi’s radical plan leaves lung cancer patients behind

By Tom Wilbur  |    October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...   Read More

Pelosi’s radical plan would leave Alzheimer’s patients behind

By Tom Wilbur  |    October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...   Read More

Pelosi’s radical plan would leave ALS patients behind

By Tom Wilbur  |    October 15, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...   Read More

What they are saying: Broad opposition to Pelosi’s radical drug pricing plan

By Tom Wilbur  |    October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An...   Read More

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

By Tom Wilbur  |    October 9, 2019
In our last IP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical...   Read More

By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

By Tom Wilbur  |    September 26, 2019
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates